

Regarding Item 5

Elections to the Supervisory Board

After Prof. Dr. Treffenfeldt stepped down from the Supervisory Board on 3 October 2024 for personal reasons, Dr. Ursula La Cognata was appointed to the Supervisory Board by court order at the request of the Management Board with effect from 11 July 2025 for the period until the end of the Annual General Meeting that will decide on the discharge of the Supervisory Board for the financial year from 1 October 2024 to 30 September 2025. For this reason, a new election by the AGM is required to fill this Supervisory Board position.

Pursuant to Section 96 (1) of the German Stock Corporation Act (AktG), the Company's Supervisory Board consists of the shareholders' Supervisory Board members, and pursuant to Section 95 AktG and Section 9 (1) of the Company's bylaws, it consists of six members elected by the AGM. The AGM is not tied to nominations.

Pursuant to the recommendation of its Audit Committee, the Supervisory Board proposes electing

Dr. Ursula La Cognata, Berlin, Managing Partner, ybe – Your Biotech Experts Partnerschaftsgesellschaft as a member of the Company's Supervisory Board with effect as of the conclusion of the AGM on 11 March 2026 until the end of the AGM that ratifies the actions of the Supervisory Board for the fiscal year from 1 October 2028 to 30 September 2029.

The nomination takes into consideration the targets that the Supervisory Board has approved for its composition, and aims to satisfy the competency profile developed for the plenary board. The targets and the competency profile are published in the corporate governance declaration for the 2024/25 fiscal year, which is included in the 2024/25 annual report and which forms part of the documents submitted in relation to agenda item 1.

To a large extent, the proposed candidate possesses the experience and expertise required to exercise the Supervisory Board mandate, as well as the necessary sector, specialist and corporate knowledge. The candidate is familiar both with the business area in which the Company operates and with the capital market environment. The Supervisory Board has satisfied itself that the candidate can devote the expected requisite amount of time to the mandate.

Supplementary disclosures and information about the proposed candidate, especially information pursuant to Section 125 (1) Sentence 5 AktG, the candidate's CV as well as further information relating to the recommendations of the German Corporate Governance Code are reproduced in Section B of this invitation and can also be viewed on the Company's website at

<https://www.brain-biotech-group.com/en/investors/annual-general-meeting/>